Dr. Kevin Wingerd was designated as the Chief Technical Officer (CTO) for the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) on 23 January 2019. As the CTO, he is an advisor to internal and external leadership, and has supervisory responsibility for technical subject matter experts. In addition, he provides technical management and professional leadership on complex issues related to joint service CBRN defense acquisition programs. He plans, directs, manages, and coordinates with the JPEO-CBRND JPM CBRN Medical’s mission objectives, and is responsible for the development, training, hiring, and retention of highly-skilled experts in the development of medical diagnostic systems, therapeutics, and vaccines. Prior to this designation, Dr. Wingerd was a senior scientist supporting the vaccine development group as a contractor from 2013 to 2018, and as a civilian from 2018 to 2019.
Prior to joining the JPEO-CBRND team, Dr. Wingerd worked at Emergent BioSolutions, Inc., in Lansing, Michigan, from 2005 to 2013. He was the senior director of process and analytical development, and provided leadership, training, and technical direction to a large staff and four laboratories. During his time at Emergent, Dr. Wingerd worked closely with the U.S. Food and Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA), to improve and scale-up anthrax vaccine manufacturing.
Dr. Wingerd earned his PhD in Molecular, Cellular, and Developmental Biology from the University of California, Santa Barbara, in 2003. He was a post-doctoral researcher at the Neuroscience Research Institute in Santa Barbara, California, from 2003 to 2005. He holds a Level III Defense Acquisition University (DAU) certification in Science and Technology Management, and is a member of the U.S. Army Acquisition Corps.
Dr. Wingerd’s awards include special commendations for his efforts in the Ebola Response, 2015, and the COVID-19 response in 2020. He has received numerous performance and time-off awards since joining the JPEO-CBRND team